Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 302.00K | 1.28M | 4.03M | 13.25M | 18.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 302.00K | 1.28M | 4.03M | 13.25M | 18.04M |
| Cost of Revenue | 66.41M | 66.19M | 27.32M | 25.28M | 27.28M |
| Gross Profit | -66.11M | -64.91M | -23.29M | -12.03M | -9.24M |
| SG&A Expenses | 23.20M | 20.62M | 16.75M | 15.09M | 13.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.51M | -- | -- | -- | -- |
| Total Operating Expenses | 108.25M | 92.49M | 49.77M | 46.06M | 46.50M |
| Operating Income | -107.95M | -91.22M | -45.74M | -32.81M | -28.46M |
| Income Before Tax | -185.59M | -170.29M | -126.10M | -114.42M | -26.33M |
| Income Tax Expenses | -- | -- | 7.00K | -25.00K | 15.00K |
| Earnings from Continuing Operations | -185.59 | -170.29 | -126.10 | -114.39 | -26.35 |
| Earnings from Discontinued Operations | 2.61M | 464.00K | 5.37M | 536.00K | -9.92M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -182.98M | -169.83M | -120.73M | -113.86M | -36.27M |
| EBIT | -107.95M | -91.22M | -45.74M | -32.81M | -28.46M |
| EBITDA | -107.79M | -91.07M | -45.59M | -32.68M | -28.34M |
| EPS Basic | -29.47 | -30.09 | -25.42 | -24.99 | -8.03 |
| Normalized Basic EPS | -7.16 | -7.26 | -5.02 | -4.07 | -3.64 |
| EPS Diluted | -29.47 | -30.09 | -25.43 | -25.00 | -8.03 |
| Normalized Diluted EPS | -7.16 | -7.26 | -5.02 | -4.07 | -3.64 |
| Average Basic Shares Outstanding | 35.00M | 25.36M | 20.16M | 18.14M | 18.08M |
| Average Diluted Shares Outstanding | 35.00M | 25.36M | 20.16M | 18.14M | 18.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |